Colorectal Cancer in Individuals with Cirrhosis: A Population-Based Study Assessing Practice Patterns, Outcomes, and Predictors of Survival
Current Oncology · 2023
DOI: 10.3390/curroncol30110690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Sunil Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Queen's University, Kingston, ON K7L 2V7, Canada. Hauptthemen laut MEDLINE: End Stage Liver Disease, Non-alcoholic Fatty Liver Disease, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ontario Association of General Surgery (OAGS), the Department of Surgery at Queen's University, and the Southeastern Ontario Academic Medical Organization, Ontario Association of General Surgery (OAGS), Department of Surgery at Queen’s University.
Abstract (Originalsprache)
Those with cirrhosis who develop colorectal cancer (CRC) are an understudied group who may tolerate treatments poorly and are at risk of worse outcomes. This is a retrospective cohort study of 842 individuals from Ontario, Canada, with a pre-existing diagnosis of cirrhosis who underwent surgery for CRC between 2009 and 2017. Practice patterns, overall survival, and short-term morbidity and mortality were assessed. The most common cirrhosis etiology was non-alcoholic fatty liver disease (NAFLD) (52%) and alcohol-associated liver disease (29%). The model for end-stage liver disease score (MELD-Na) was available in 42% (median score of 9, IQR7-11). Preoperative radiation was used in 62% of Stage II/III rectal cancer patients, while postoperative chemotherapy was used in 42% of Stage III colon cancer patients and 38% of Stage II/III rectal cancer patients. Ninety-day mortality following surgery was 12%. Five-year overall survival was 53% (by Stages I–IV, 66%, 55%, 50%, and 11%, respectively). Those with alcohol-associated cirrhosis (HR 1.8, 95% CI 1.5–2.2) had lower survival than those with NAFLD. Those with a MELD-Na of 10+ did worse than those with a lower MELD-Na score (HR 1.9, 95% CI 1.4–2.6). This study reports poor survival in those with cirrhosis who undergo treatment for CRC. Caution should be taken when considering aggressive treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Queen's University, Kingston, ON K7L 2V7, Canada.
- Cancer Care and Epidemiology, Queens Cancer Research Institute, Kingston, ON K7L 3N6, Canada.
- Department of Surgery, Ottawa University, Ottawa, ON K1H 8L6, Canada.
- ICES Queens, Kingston, ON K7L 3L4, Canada.
- Department of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
Förderung
- Ontario Association of General Surgery (OAGS), the Department of Surgery at Queen's University, and the Southeastern Ontario Academic Medical Organization
- Ontario Association of General Surgery (OAGS)
- Department of Surgery at Queen’s University
- Southeastern Ontario Academic Medical Organization
Zitieren
APA
Patel, S., Brennan, K., Zhang, L., Djerboua, M., Nanji, S., Merchant, S., & Flemming, J. (2023). Colorectal Cancer in Individuals with Cirrhosis: A Population-Based Study Assessing Practice Patterns, Outcomes, and Predictors of Survival. Current Oncology. https://doi.org/10.3390/curroncol30110690
Vancouver
Patel S, Brennan K, Zhang L, Djerboua M, Nanji S, Merchant S, et al. Colorectal Cancer in Individuals with Cirrhosis: A Population-Based Study Assessing Practice Patterns, Outcomes, and Predictors of Survival. Current Oncology. 2023. doi:10.3390/curroncol30110690
BibTeX
@article{Patel2023,
author = {Patel, Sunil and Brennan, Kelly and Zhang, Lisa and Djerboua, Maya and Nanji, Sulaiman and Merchant, Shaila and Flemming, Jennifer},
title = {Colorectal Cancer in Individuals with Cirrhosis: A Population-Based Study Assessing Practice Patterns, Outcomes, and Predictors of Survival},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30110690}
}
EUVIMED